We also examine emerging therapeutic strategies targeting Regnase activity, including antisense oligonucleotides to enhance Regnase-1 expression, gene- and RNA-based delivery approaches, and selective inhibition of Regnase-1 in T cells to boost cancer immunotherapy. This evidence concerns the gene ZC3H12A and cancer.